25% More Jobs Thanks To A Structural Commitment Of 500,000 Euro Per Year.

The European leader in healthcare product logistics, CSP (Centre Spécialités Pharmaceutiques), celebrated the 10th anniversary of its Benelux headquarters on Tuesday 20 November and announced large-scale expansion projects.

On the occasion of the celebration of the 10th anniversary, in the presence of shareholders, customers and authorities, CSP BENELUX announced that from next year, work will begin to extend 50% of its GDP infrastructure. This growth should enable CSP Benelux to continue to meet the growing market demand and will result in a 25% increase in its workforce. The structural commitment amounts to 500,000,- Euro on an annual basis.

CSP BENELUX offers a complete solution for logistics, intermediate storage and temperature-controlled transport, guaranteeing that the quality of pharmaceutical products is maintained until the end customer, in accordance with GDP* standards. CSP Benelux also provides serialization marking, in accordance with the European FMD** directive against counterfeit medicines.

In its warehouse in Houdeng-Goegnies, storage is maintained at +2°C/+8°C or +15°C/+25°C, pharmaceutical order preparation also includes sensitive products, clinical tests, medical samples and drug delivery throughout the Benelux.

In addition, CSP BENELUX provides additional services of very high quality, thanks to the latest technological advances and its specially trained staff in compliance with the pharmaceutical code of conduct and GMP* manufacturing methods. The pharmaceutical industry, distributors, wholesalers, hospitals and pharmacies recognize the know-how and reliability of the services offered.

CSP Benelux is a company of French origin established since 2008 in Belgium in the "Pharma Valley" of Hainaut with also an office in Nijmegen, in the Netherlands under the name of Eurotranspharma Netherlands.

*GDP: Good Distribution Practices - GMP: Good Manufacturing Practices

**: From 2019 onwards, each package of a prescription drug in Europe will have to bear a unique serial number registered in a central database.